Overall rank by patents
#29,695
of 49,997 tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Oramed Ltd.
USPTO PatentsView assignee record - 9 granted patents across 2 technology areas, recorded in grant years 2018–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Oramed ranks #29,695 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 2 technology areas.
- #29,695
- of 49,997 US assignees by volume
- 32nd percentile
- by Innovation Score (29.9/100)
- 24.6
- avg claims per patent
- +25%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R29695 · Foreign Corporation #29,695 · 9 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-UP · BOOK-FULL
- GRANTS-MICRO 9 grants
- MID-PACK #29,695/49,997
- PHOTO-FINISH Opiant Pharmaceuticals
- CPC-NARROW A61P · 2 areas
- INNOV-THIN 29.9/100
- CLAIMS-DENSE 24.6 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-UP +25% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Opiant Pharmaceuticals, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Innovation-score neighbourhood around Oramed
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Oramed · this assignee 30
Oramed · this assignee
30 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Oramed's Innovation Score is 29.9/100 (32nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Where Oramed's grants concentrate
Oramed Ltd. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2018. By volume, Oramed sits between Opiant Pharmaceuticals, Inc. and Original, Inc..
Oramed's three-year grant acceleration
Oramed Ltd. shows 2 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Oramed's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Opiant Pharmaceut…
Opiant Pharmaceuticals, Inc.
9 patents
- Optellum
Optellum Limited
9 patents
- Optilab
Optilab, LLC
9 patents
- Optuminsight
OptumInsight, Inc.
9 patents
- Orca Biosystems
Orca Biosystems, Inc.
9 patents
- Ordr
Ordr Inc.
9 patents
- Orege
Orege
9 patents
- Original
Original, Inc.
9 patents
- Oramed ◀
Oramed Ltd.
9 patents
What this shows Oramed holds 9 patents at rank #29,680, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Oramed
By rank, the assignees closest to #29,680 in granted patent volume.
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Oramed's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Oramed's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
30 32nd percentile higher than 32% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 1 | 11.1% |
| 2019 | 3 | 33.3% |
| 2021 | 3 | 33.3% |
| 2022 | 1 | 11.1% |
| 2023 | 1 | 11.1% |
Which technologies does Oramed Ltd. patent most?
Top 2 of 2 technology areas
What to do with this data
Oramed Ltd.'s patent record in context - here's where to go next.
- Oramed Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #29,695 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Oramed Ltd. against Opiant Pharmaceuticals, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 29.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.